{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:02:27Z","timestamp":1790744547798,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major cause of morbidity and mortality worldwide. The introduction of direct oral anticoagulants (DOACs) has transformed the management of VTE by providing effective and convenient alternatives to vitamin K antagonists. However, despite their favorable efficacy\u2013safety profile, clinically relevant bleeding, treatment individualization, and the management of patients with competing thrombotic and hemorrhagic risks remain important unmet clinical needs. Contemporary VTE management increasingly requires a personalized approach integrating clinical characteristics, comorbidities, biomarkers, and real-world evidence to optimize anticoagulant selection, treatment intensity, and duration. Large prospective registries have expanded our understanding of VTE across heterogeneous clinical settings, including cancer-associated thrombosis, postoperative VTE, incidental and subsegmental pulmonary embolism, and other high-risk populations frequently underrepresented in randomized clinical trials. In parallel, emerging prognostic tools, including D-dimer, hemoglobin, inflammatory indices, lipid-related biomarkers, and machine-learning-based prediction models, are contributing to a more refined assessment of thrombotic and bleeding risk. These emerging therapies are being evaluated as potential strategies to reduce bleeding while maintaining antithrombotic efficacy; however, recent phase III findings have demonstrated heterogeneous efficacy across clinical indications, emphasizing that their future role is likely to be indication-specific. This narrative review examines the current role of DOACs in VTE management, discusses the clinical and biological determinants of individualized anticoagulant therapy, and critically appraises the evolving and heterogeneous evidence for Factor XI inhibition as a potential future anticoagulant strategy.<\/jats:p>","DOI":"10.3389\/fphar.2026.1959476","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:53:58Z","timestamp":1790744038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition"],"prefix":"10.3389","volume":"17","author":[{"given":"Carmine","family":"Siniscalchi","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Parma University Hospital","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Perrella","sequence":"additional","affiliation":[{"name":"Emerging Infectious Disease and High Contagiousness Unit P.O. D. Cotugno-AORN Ospedali dei Colli","place":["Naples, Italy"]},{"name":"Regional Observatory for Infectious Disease","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Trama","sequence":"additional","affiliation":[{"name":"Coordination of the Regional Health System, General Directorate for Health Protection","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Basaglia","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Parma University Hospital","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Futura","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Coordination of the Regional Health System, General Directorate for Health Protection","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Di Micco","sequence":"additional","affiliation":[{"name":"Internal Medicine Ward \u201cP.O. Santa Maria delle Grazie\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer (CARAVAGGIO)","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/joim.12969","article-title":"D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry","volume":"287","author":"Avnery","year":"2020","journal-title":"J. Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e021467","DOI":"10.1161\/JAHA.121.021467","article-title":"Association between preexisting Versus newly identified atrial fibrillation and outcomes of patients with acute pulmonary embolism","volume":"10","author":"Bikdeli","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/v14020178","article-title":"Venous thrombosis within 30 days after vaccination against SARS-CoV-2 in a multinational venous thromboembolism registry","volume":"14","author":"Bikdeli","year":"2022","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3324\/haematol.2012.073601","article-title":"Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation","volume":"98","author":"Bloemen","year":"2013","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2022.11.007","article-title":"Deep vein thrombosis symptoms and 30-day mortality in acute pulmonary embolism","volume":"108","author":"Dubois-Silva","year":"2023","journal-title":"Eur. J. Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jvsv.2020.11.017","article-title":"Timing and characteristics of venous thromboembolism after noncancer surgery","volume":"9","author":"Exp\u00f3sito-Ruiz","year":"2021","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/rth2.12446","article-title":"Symptomatic subsegmental versus more central pulmonary embolism: clinical outcomes during anticoagulation","volume":"5","author":"Fern\u00e1ndez-Capit\u00e1n","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jvsv.2019.03.011","article-title":"Registro Informatizado de Enfermedad Tromboemb\u00f3lica Investigators. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: findings from the Registro Informatizado de Enfermedad Tromboemb\u00f3lica Registry","volume":"8","author":"Golemi","year":"2020","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of Factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jama.296.4.397","article-title":"Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation","volume":"296","author":"Hron","year":"2006","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Investigators","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1901647","DOI":"10.1183\/13993003.01647-2019","article-title":"ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology (ESC)","volume":"54","author":"Konstantinides","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American society of hematology 2021 guidelines for management of venous thromboembolism in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1801677","DOI":"10.1183\/13993003.01677-2018","article-title":"Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry","volume":"53","author":"Mastroiacovo","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation Factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11739-019-02077-5","article-title":"Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism","volume":"14","author":"Mellado","year":"2019","journal-title":"Intern Emerg. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv."},{"key":"B33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/bjh.18737","article-title":"Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations","volume":"201","author":"Mora","year":"2023","journal-title":"Br. J. Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2002723","DOI":"10.1183\/13993003.02723-2020","article-title":"Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism","volume":"58","author":"Peris","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral Factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13023-019-1172-8","article-title":"Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry","volume":"14","author":"Riera-Mestre","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1055\/a-2521-0923","article-title":"Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: a nested case-control Study","volume":"125","author":"Shaw","year":"2025","journal-title":"Thromb. Haemost."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/ajh.27379","article-title":"The prognostic value of blood cellular indices in pulmonary embolism","volume":"99","author":"Siddiqui","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch. Intern Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejim.2019.07.028","article-title":"Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry","volume":"68","author":"Siniscalchi","year":"2019","journal-title":"Eur. J. Intern Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/jth.15753","article-title":"Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism","volume":"20","author":"Siniscalchi","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/cells12232719","article-title":"Statins effects on blood clotting: a review","volume":"12","author":"Siniscalchi","year":"2023","journal-title":"Cells"},{"key":"B50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.thromres.2024.02.024","article-title":"Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE registry","volume":"236","author":"Siniscalchi","year":"2024","journal-title":"Thromb. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e259467","DOI":"10.1001\/jamanetworkopen.2025.9467","article-title":"Low-density lipoprotein cholesterol levels and bleeding risk in venous thromboembolism","volume":"8","author":"Siniscalchi","year":"","journal-title":"JAMA Netw. Open"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ajh.27707","article-title":"Baseline hemoglobin values and clinical outcomes in acute venous thromboembolism: insights from the RIETE registry","volume":"100","author":"Siniscalchi","year":"","journal-title":"Am. J. Hematol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.3390\/jcm15062370","article-title":"Machine learning models for predicting bleeding risk in anticoagulated patients with atrial fibrillation and venous thromboembolism: a comparative evidence synthesis","volume":"15","author":"Teo","year":"2026","journal-title":"J. Clin. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1538-7836.2008.03018.x","article-title":"High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism","volume":"6","author":"Tripodi","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"Undas","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/MCP.0b013e32832ee371","article-title":"Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms","volume":"15","author":"Wattanakit","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral Factor Xa inhibitor with low molecular weight heparin in patients with cancer-associated venous thromboembolism (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1959476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:54:05Z","timestamp":1790744045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1959476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":62,"alternative-id":["10.3389\/fphar.2026.1959476"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1959476","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1959476"}}